1,891 reports of this reaction
1.2% of all ERENUMAB AOOE reports
#15 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #15 most commonly reported adverse reaction for ERENUMAB AOOE, manufactured by Amgen Inc. There are 1,891 FDA adverse event reports linking ERENUMAB AOOE to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 1.2% of all 151,566 adverse event reports for this drug.
Patients taking ERENUMAB AOOE who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is a less commonly reported adverse event for ERENUMAB AOOE, but still significant enough to appear in the safety profile.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for ERENUMAB AOOE:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 1,891 FDA reports for ERENUMAB AOOE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 1.2% of all adverse event reports for ERENUMAB AOOE, making it a notable side effect.
If you experience therapeutic product effect incomplete while taking ERENUMAB AOOE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.